Muss H B, Bundy B N, Adcock L
Bowman Gray School of Medicine, Wake Forest University, Winston-Salem, North Carolina.
Am J Clin Oncol. 1991 Feb;14(1):36-7. doi: 10.1097/00000421-199102000-00008.
Twenty-two evaluable patients with advanced endometrial cancer were treated with teniposide 100 mg/m2/week administered as a 30-60-minute infusion. Escalations of 20 mg/m2/week to a maximum dose of 160 mg/m2 were performed in patients without toxicity. Seventeen of the 22 patients had prior chemotherapy. Two patients had a partial response (95% upper confidence bound for response: 25.9%). Toxicity was minimal. Four patients had white blood cell counts of less than 2,000/mm3 but only two with less than 1,000/mm3. Only one patient had a platelet count between 25,000 and 50,000, and no bleeding or septic episodes were noted. Four patients had mild nausea, and eight mild nausea and vomiting. Teniposide displays no major activity in patients with advanced endometrial cancer who have had prior chemotherapy.
22例可评估的晚期子宫内膜癌患者接受了替尼泊苷治疗，剂量为100mg/m²/周，静脉输注30 - 60分钟。对未出现毒性反应的患者，剂量以20mg/m²/周递增，最大剂量为160mg/m²。22例患者中有17例曾接受过化疗。2例患者出现部分缓解（缓解率的95%置信上限：25.9%）。毒性反应轻微。4例患者白细胞计数低于2000/mm³，但仅有2例低于1000/mm³。仅有1例患者血小板计数在25000至50000之间，未观察到出血或感染发作。4例患者出现轻度恶心，8例出现轻度恶心和呕吐。对于曾接受过化疗的晚期子宫内膜癌患者，替尼泊苷未显示出主要活性。
